Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Jenkins

Showing results (641-650 of 799) with videos related to

Pageof 80
Sort By:
Inorganic Chemistry|February 25, 2009
77Se NMR spectroscopic, DFT MO, and VBT investigations of the reversible dissociation of solid (Se6I2)[AsF6]2.2SO2 in Liquid SO2 to solutions containing 1,4-Se6I2(2+) in equilibrium with Se(n)2+ (n = 4, 8, 10) and seven binary selenium iodine cations: preliminary evidence for 1,1,4,4-Se4Br4(2+) and cyclo-Se7Br+Scott Brownridge, Larry Calhoun, H Donald B Jenkins, et al.
Neuro-Oncology Advances|February 27, 2023
Genomic markers of recurrence risk in atypical meningioma following gross total resectionRachael A Vaubel, Rahul Kumar, Taylor M Weiskittel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2005
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group StudyEvanthia Galanis, Jan C Buckner, Matthew J Maurer, et al.
Genes, Chromosomes & Cancer|May 5, 2018
Copy number variant analysis using genome-wide mate-pair sequencingJames B Smadbeck, Sarah H Johnson, Stephanie A Smoley, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 16, 2018
Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate CancerRobert J Rounbehler, Anders E Berglund, Travis Gerke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2001
Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancerS K McDonnell, D J Schaid, J L Myers, et al.
Genes, Chromosomes & Cancer|May 31, 2022
Typical, atypical and cryptic t(15;17)(q24;q21) (PML::RARA) observed in acute promyelocytic leukemia: A retrospective review of 831 patients with concurrent chromosome and PML::RARA dual-color dual-fusion FISH studiesMarie-France Gagnon, Holly E Berg, Reid G Meyer, et al.
Acta Neuropathologica Communications|November 7, 2018
Novel BRAF alteration in desmoplastic infantile ganglioglioma with response to targeted therapyMelissa M Blessing, Patrick R Blackburn, Jessica R Balcom, et al.
Journal of Neuropathology and Experimental Neurology|August 7, 2021
Polymorphous Low-Grade Neuroepithelial Tumor of the Young (PLNTY): Molecular Profiling Confirms Frequent MAPK Pathway ActivationCristiane M Ida, Derek R Johnson, Asha A Nair, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2013
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trialEdith A Perez, Amylou C Dueck, Ann E McCullough, et al.
Pageof 80

Showing results (641-650 of 799) with videos related to

Sort By:
Pageof 80
Inorganic Chemistry|February 25, 2009
77Se NMR spectroscopic, DFT MO, and VBT investigations of the reversible dissociation of solid (Se6I2)[AsF6]2.2SO2 in Liquid SO2 to solutions containing 1,4-Se6I2(2+) in equilibrium with Se(n)2+ (n = 4, 8, 10) and seven binary selenium iodine cations: preliminary evidence for 1,1,4,4-Se4Br4(2+) and cyclo-Se7Br+Scott Brownridge, Larry Calhoun, H Donald B Jenkins, et al.
Neuro-Oncology Advances|February 27, 2023
Genomic markers of recurrence risk in atypical meningioma following gross total resectionRachael A Vaubel, Rahul Kumar, Taylor M Weiskittel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2005
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group StudyEvanthia Galanis, Jan C Buckner, Matthew J Maurer, et al.
Genes, Chromosomes & Cancer|May 5, 2018
Copy number variant analysis using genome-wide mate-pair sequencingJames B Smadbeck, Sarah H Johnson, Stephanie A Smoley, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 16, 2018
Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate CancerRobert J Rounbehler, Anders E Berglund, Travis Gerke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2001
Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancerS K McDonnell, D J Schaid, J L Myers, et al.
Genes, Chromosomes & Cancer|May 31, 2022
Typical, atypical and cryptic t(15;17)(q24;q21) (PML::RARA) observed in acute promyelocytic leukemia: A retrospective review of 831 patients with concurrent chromosome and PML::RARA dual-color dual-fusion FISH studiesMarie-France Gagnon, Holly E Berg, Reid G Meyer, et al.
Acta Neuropathologica Communications|November 7, 2018
Novel BRAF alteration in desmoplastic infantile ganglioglioma with response to targeted therapyMelissa M Blessing, Patrick R Blackburn, Jessica R Balcom, et al.
Journal of Neuropathology and Experimental Neurology|August 7, 2021
Polymorphous Low-Grade Neuroepithelial Tumor of the Young (PLNTY): Molecular Profiling Confirms Frequent MAPK Pathway ActivationCristiane M Ida, Derek R Johnson, Asha A Nair, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2013
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trialEdith A Perez, Amylou C Dueck, Ann E McCullough, et al.
Pageof 80